FAQ/Help |
Calendar |
Search |
Today's Posts |
11-29-2013, 07:09 PM | #1 | ||
|
|||
Senior Member
|
Would a therapy that slowed progression by x% in y% of PwP pass clinical trials?
My worry is that potential therapies to slow the progression of PD may be being ignored. Let me explain why. If you had a therapy that stopped progression for everyone, it would be easy to see that it was effective: after 6 months, or whatever, almost everyone in the control group would have declined, whereas all those taking the treatment would be no worse. But what about a therapy that slowed progression by 10% for 50% of people and had no difference for the remaining 50%? Or one that slowed progression for women by 5%, but increased progression rates for men by 5%? Not only do the latter cases have lower net benefit, but they increase the variance of the sample, making it harder to show statistical significance. A better approach is, I believe, patient centred trials with high frequency testing. John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
GM1 ganglioside improved symptoms and slowed their progression during a two and a hal | Parkinson's Disease | |||
Clinical trials for SFN? | Peripheral Neuropathy | |||
Nicotine Could Ease Symptoms Of Parkinson's DiseaseStudy Suggests Progression Slowed | ALS News & Research | |||
Looking at clinical trials | Parkinson's Disease Clinical Trials | |||
Clinical Trials | Reflex Sympathetic Dystrophy (RSD and CRPS) |